What were we asked to look at?
We were asked to provide a high level overview of The Dxcover™ spectroscopic liquid biopsy test.
This test is based on machine learning to identify and compare patterns in the biochemical profile of serum from patients with and without brain cancer. The test uses diagnostic algorithms to analyse spectra from samples provided by patients suspected of having brain cancer to predict which patients are likely to have the disease.
Why is this important?
There is no biomarker test for brain tumours. The innovative aspect of this test is that, rather than focusing on a single biomarker for disease, the test algorithm utilises the full biological profile of the serum sample. No specialist sample preparation is required and results are available within minutes.
Dxcover Limited, manufacturer of the technology
Quality assurance and sign-off.